Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia
- 31 October 2004
- journal article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 44 (4), 757-761
- https://doi.org/10.1053/j.ajkd.2004.06.016
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The detection of anti-erythropoietin antibodies in human serum and plasma: Part I. Validation of the protocol for a radioimmunoprecipitation assayJournal of Immunological Methods, 2003
- Immunogenicity of therapeutic proteins.Nephrology Dialysis Transplantation, 2003
- Pure red-cell aplasia due to anti-erythropoietin antibodiesNephrology Dialysis Transplantation, 2003
- PRCA in a patient treated with epoetin betaNephrology Dialysis Transplantation, 2003
- Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapyAmerican Journal of Kidney Diseases, 2003
- Rituximab for the treatment of refractory autoimmune hemolytic anemia in childrenBlood, 2003
- Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemiaBone Marrow Transplantation, 2002
- Rituximab for the treatment of type II mixed cryoglobulinemiaArthritis & Rheumatism, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Pure red cell aplasiaBritish Journal of Haematology, 2000